AOD 9604

• Form: Lyophilized powder
• Purity: >99%

Overview

AOD 9604 is a synthetic analog of human growth hormone (hGH), specifically derived from the C-terminal fragment 176–191. This modified peptide was developed to investigate potential anti-obesity properties without stimulating Insulin-like Growth Factor 1 (IGF-1) production. Researchers often refer to it as GH Fragment 176-191 or simply AOD 9604. To improve stability, the peptide includes a tyrosine substitution at the N-terminus.

Research Background

AOD 9604 is considered the lipolytic fragment of hGH. Different regions of hGH display distinct biological actions:

• The N-terminal region has been associated with insulin-potentiating effects.
• Amino acids 108–129 appear to show high mitogenic activity.
• The 176–191 fragment has been linked to lipolysis and fat metabolism.

Developed in the 1990s, AOD 9604 was designed to explore selective fat-reducing effects of growth hormone while minimizing undesired anabolic or mitogenic actions.

Mechanism of Interest

• Lipolysis: the breakdown of stored triglycerides into glycerol and free fatty acids.
• Beta-adrenergic receptors (β3-AR): animal studies indicate increased RNA expression of β3-AR in fat cells following exposure to AOD 9604, which may enhance receptor sensitivity to lipolytic stimuli.
• Non-IGF pathways: unlike full-length hGH, AOD 9604 appears to act independently of IGF-1 stimulation.

The exact mechanism remains under study. AOD 9604 is consistently investigated for its potential role in fat metabolism and weight regulation.

Molecular Information

• Molecular Formula: C78H123N23O23S2
• Molecular Weight: 1815.12 g/mol
• Other Names: Tyr-hGH Fragment 177–191